262 related articles for article (PubMed ID: 18842625)
21. In Vivo Evaluation of Multiple Exon Skipping with Peptide-PMOs in Cardiac and Skeletal Muscles in Dystrophic Dogs.
Maruyama R; Aoki Y; Takeda S; Yokota T
Methods Mol Biol; 2018; 1828():365-379. PubMed ID: 30171554
[TBL] [Abstract][Full Text] [Related]
22. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides.
Wilton SD; Lloyd F; Carville K; Fletcher S; Honeyman K; Agrawal S; Kole R
Neuromuscul Disord; 1999 Jul; 9(5):330-8. PubMed ID: 10407856
[TBL] [Abstract][Full Text] [Related]
23. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides.
Dunckley MG; Manoharan M; Villiet P; Eperon IC; Dickson G
Hum Mol Genet; 1998 Jul; 7(7):1083-90. PubMed ID: 9618164
[TBL] [Abstract][Full Text] [Related]
24. Induced dystrophin exon skipping in human muscle explants.
McClorey G; Fall AM; Moulton HM; Iversen PL; Rasko JE; Ryan M; Fletcher S; Wilton SD
Neuromuscul Disord; 2006 Oct; 16(9-10):583-90. PubMed ID: 16919955
[TBL] [Abstract][Full Text] [Related]
25. Functionalized PEG-PEI copolymers complexed to exon-skipping oligonucleotides improve dystrophin expression in mdx mice.
Sirsi SR; Schray RC; Guan X; Lykens NM; Williams JH; Erney ML; Lutz GJ
Hum Gene Ther; 2008 Aug; 19(8):795-806. PubMed ID: 18647087
[TBL] [Abstract][Full Text] [Related]
26. In Vitro Multiexon Skipping by Antisense PMOs in Dystrophic Dog and Exon 7-Deleted DMD Patient.
Nakamura A; Aoki Y; Tsoumpra M; Yokota T; Takeda S
Methods Mol Biol; 2018; 1828():151-163. PubMed ID: 30171540
[TBL] [Abstract][Full Text] [Related]
27. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping.
Goyenvalle A; Vulin A; Fougerousse F; Leturcq F; Kaplan JC; Garcia L; Danos O
Science; 2004 Dec; 306(5702):1796-9. PubMed ID: 15528407
[TBL] [Abstract][Full Text] [Related]
28. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
[TBL] [Abstract][Full Text] [Related]
29. Parallel synthesis and splicing redirection activity of cell-penetrating peptide conjugate libraries of a PNA cargo.
Deuss PJ; Arzumanov AA; Williams DL; Gait MJ
Org Biomol Chem; 2013 Nov; 11(43):7621-30. PubMed ID: 24105028
[TBL] [Abstract][Full Text] [Related]
30. Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells.
Lehto T; Castillo Alvarez A; Gauck S; Gait MJ; Coursindel T; Wood MJ; Lebleu B; Boisguerin P
Nucleic Acids Res; 2014 Mar; 42(5):3207-17. PubMed ID: 24366877
[TBL] [Abstract][Full Text] [Related]
31. Cyclic Peptides to Improve Delivery and Exon Skipping of Antisense Oligonucleotides in a Mouse Model for Duchenne Muscular Dystrophy.
Jirka SMG; 't Hoen PAC; Diaz Parillas V; Tanganyika-de Winter CL; Verheul RC; Aguilera B; de Visser PC; Aartsma-Rus AM
Mol Ther; 2018 Jan; 26(1):132-147. PubMed ID: 29103911
[TBL] [Abstract][Full Text] [Related]
32. PNA-peptide conjugates as intracellular gene control agents.
Ivanova GD; Fabani MM; Arzumanov AA; Abes R; Yin H; Lebleu B; Wood M; Gait MJ
Nucleic Acids Symp Ser (Oxf); 2008; (52):31-2. PubMed ID: 18776238
[TBL] [Abstract][Full Text] [Related]
33. Ex vivo gene editing of the dystrophin gene in muscle stem cells mediated by peptide nucleic acid single stranded oligodeoxynucleotides induces stable expression of dystrophin in a mouse model for Duchenne muscular dystrophy.
Nik-Ahd F; Bertoni C
Stem Cells; 2014 Jul; 32(7):1817-30. PubMed ID: 24753122
[TBL] [Abstract][Full Text] [Related]
34. Bi-specific splice-switching PMO oligonucleotides conjugated via a single peptide active in a mouse model of Duchenne muscular dystrophy.
Shabanpoor F; McClorey G; Saleh AF; Järver P; Wood MJ; Gait MJ
Nucleic Acids Res; 2015 Jan; 43(1):29-39. PubMed ID: 25468897
[TBL] [Abstract][Full Text] [Related]
35. Peptide-morpholino conjugate: a promising therapeutic for Duchenne muscular dystrophy.
Moulton HM; Wu B; Jearawiriyapaisarn N; Sazani P; Lu QL; Kole R
Ann N Y Acad Sci; 2009 Sep; 1175():55-60. PubMed ID: 19796077
[TBL] [Abstract][Full Text] [Related]
36. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
Maruyama R; Yokota T
Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
[TBL] [Abstract][Full Text] [Related]
37. Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy.
Cao L; Han G; Gu B; Yin H
PLoS One; 2014; 9(11):e111079. PubMed ID: 25365558
[TBL] [Abstract][Full Text] [Related]
38. In Vivo Evaluation of Single-Exon and Multiexon Skipping in mdx52 Mice.
Mizobe Y; Miyatake S; Takizawa H; Hara Y; Yokota T; Nakamura A; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1828():275-292. PubMed ID: 30171548
[TBL] [Abstract][Full Text] [Related]
39. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse.
Lu QL; Mann CJ; Lou F; Bou-Gharios G; Morris GE; Xue SA; Fletcher S; Partridge TA; Wilton SD
Nat Med; 2003 Aug; 9(8):1009-14. PubMed ID: 12847521
[TBL] [Abstract][Full Text] [Related]
40. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy.
Takeshima Y; Yagi M; Wada H; Ishibashi K; Nishiyama A; Kakumoto M; Sakaeda T; Saura R; Okumura K; Matsuo M
Pediatr Res; 2006 May; 59(5):690-4. PubMed ID: 16627883
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
